PCRX
Pacira BioSciences, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -3.9% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 89 | +2 | 30.85M | $781.81M | +7 | −4 |
| Q1 2026 | 89 | -5 | 30.76M | $694.94M | +2 | −7 |
| Q4 2025 | 94 | -1 | 36.25M | $938.05M | — | −1 |
| Q3 2025 | 19 | +1 | 24.74M | $637.46M | +2 | −1 |
| Q2 2025 | 15 | 0 | 22.66M | $541.65M | +1 | −1 |
| Q1 2025 | 12 | -3 | 10.29M | $255.59M | — | −3 |
| Q4 2024 | 15 | +1 | 11.71M | $220.69M | +1 | — |
| Q3 2024 | 13 | 0 | 9.23M | $138.98M | +1 | −1 |
| Q2 2024 | 13 | — | 6.89M | $197.00M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 7.80M | — | $186.33M | 0.0% | n/c | 1 | SEC ↗ ×17 |
| 2 | The Vanguard Group ✦ (passive) | 5.41M | — | $129.20M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 3 | Renaissance Technologies ✦ | 2.40M | +6.9% | $57.25M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 4 | D. E. Shaw & Co. ✦ | 2.25M | -0.5% | $53.86M | 0.1% | ▼ Trim | 5 | SEC ↗ ×4 |
| 5 | State Street Global Advisors ✦ (passive) | 1.95M | -1.4% | $46.62M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 1.14M | +0.5% | $27.33M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 7 | Wellington Management ✦ | 545.60K | +1.6% | $13.04M | 0.0% | ▲ Add | 5 | SEC ↗ ×5 |
| 8 | Millennium Management ✦ | 515.02K | +49.0% | $12.31M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 9 | Marshall Wace ✦ | 190.37K | New | $4.55M | 0.0% | New | 1 | SEC ↗ ×2 |
| 10 | AQR Capital Management ✦ | 142.16K | -19.6% | $3.40M | 0.0% | ▼ Trim | 5 | SEC ↗ ×4 |
| 11 | Two Sigma Investments ✦ | 106.84K | -9.7% | $2.55M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 12 | Fidelity (FMR) ✦ | 92.68K | — | $2.22M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 13 | T. Rowe Price ✦ | 47.91K | +6.5% | $1.15M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 14 | Gotham Asset Management ✦ | 42.16K | -2.3% | $1.01M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 15 | Arrowstreet Capital ✦ | 35.61K | -47.3% | $850,983 | 0.0% | ▼ Trim | 5 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $4.55M | 0.0% |
Exited
| Citadel Advisors | $33.05M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 3 holders, 13.02M shares, $12.57M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 6.00K sh · $217,920
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology